FDA Accepts Byondis' Biologics License Application for [Vic-] Trastuzumab Duocarmazine (SYD985) in HER2-Positive Metastatic Breast Cancer

/PRNewswire/ -- Byondis B.V., an independent, Dutch clinical stage biopharmaceutical company creating precision medicines, announced today that the U.S. Food &...

Related Keywords

Netherlands ,Nijmegen ,Gelderland ,Dutch ,Prnewswire Byondis ,Marco Timmers ,Trastuzumab Duocarmazine ,Cherney Kristeen ,Jan Schellens ,Drug Technology ,Us Food Drug Administration ,Submission Follows Positive Results ,Byondis Technologies Aimed ,Improving Treatment Outcomes ,Drug Administration ,Biologics License Application ,Prescription Drug User Fee Act ,Byondis Chief Medical Officer Jan Schellens ,Next Generation Antibody Drug ,Byondi Distinctive ,Proprietary Linker Drug ,Good Manufacturing Practice ,Positive Breast ,Understanding Your Outlook ,Byondisbv ,